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Hepatitis A virus (HAV) encodes a single polyprotein which is posttranslationally processed into the
functional structural and nonstructural proteins. Only one protease, viral protease 3C, has been implicated in
the nine protein scissions. Processing of the capsid protein precursor region generates a unique intermediate,
PX (VP1-2A), which accumulates in infected cells and is assumed to serve as precursor to VP1 found in virions,
although the details of this reaction have not been determined. Coexpression in transfected cells of a variety
of P1 precursor proteins with viral protease 3C demonstrated efficient production of PX, as well as VP0 and
VP3; however, no mature VP1 protein was detected. To identify the C-terminal amino acid residue of HAV VP1,
we performed peptide sequence analysis by protease-catalyzed [18O]H2O incorporation followed by liquid
chromatography ion-trap microspray tandem mass spectrometry of HAV VP1 isolated from purified virions.
Two different cell culture-adapted isolates of HAV, strains HM175pE and HM175p35, were used for these
analyses. VP1 preparations from both virus isolates contained heterogeneous C termini. The predominant
C-terminal amino acid in both virus preparations was VP1-Ser274, which is located N terminal to a methionine
residue in VP1-2A. In addition, the analysis of HM175pE recovered smaller amounts of amino acids VP1-
Glu273 and VP1-Thr272. In the case of HM175p35, which contains valine at amino acid position VP1-273,
VP1-Thr272 was found in addition to VP1-Ser274. The data suggest that HAV 3C is not the protease respon-
sible for generation of the VP1 C terminus. We propose the involvement of host cell protease(s) in the
production of HAV VP1.
Hepatitis A virus (HAV) is the sole member of the Hepato-
virus genus within the family Picornaviridae. The capsid of
HAV encloses a single-stranded RNA genome of about 7.5 kb
which is translated into a single polyprotein. The virion pro-
teins VP1 to VP4 and the nonstructural proteins are generated
from the polyprotein by a cascade of proteolytic cleavages.
Although the overall strategy of virus replication and most of
the viral proteins are conserved among all of the picornavi-
ruses, including HAV, the details of polyprotein cleavage differ
considerably among the various picornavirus genera. For ex-
ample, in enteroviruses and rhinoviruses, the primary cleavage
that releases the structural protein precursor is mediated by 2A
protease at the VP1/2A junction (40, 44). Cardiovirus polypro-
teins undergo an intramolecular autocatalytic reaction caused
by strained peptide bonds in the sequences surrounding the
scissile 2A/2B bond, followed by 3C-mediated cleavage be-
tween VP1 and 2A (28). A similar reaction occurs in aphtho-
viruses, whose 2A coding region consists of only a 16-amino-
acid sequence homologous to the C terminus of the cardiovirus
2A gene (35). In HAV, viral protease 3C (3Cpro) has been
reported to be responsible for all protein scissions (37, 38); the
2A protein has neither inherent nor catalytic proteolytic func-
tion (19, 22). The primary cleavage to release the capsid pro-
tein from the HAV polyprotein is mediated by 3Cpro between
2A and 2B at amino acids Gln836 and Ala837 (25). 3Cpro is
also responsible for the cleavage within the structural proteins
between VP3/VP2 and VP2/VP1 (24). This processing of the
capsid protein precursor region of HAV generates a unique
38- to 40-kDa intermediate, PX (VP1-2A) (1), which is thought
to subsequently yield VP1. Although evidence has been pre-
sented that 3Cpro could catalyze scission of a peptide contain-
ing VP1-2A sequences (37), the details of VP1 formation from
its presumed precursor have not been elucidated, and the
terminal amino acids of the resulting VP1 and 2A products
have not been identified biochemically. A cleavage site at
amino acid residue VP1-300 was initially proposed by sequence
alignment analysis (8), which proved to be incorrect (14).
Based on the assumption that 3C is the protease responsible
for the cleavage within the VP1-2A sequence, several potential
3C cleavage sites were proposed. Modeling of the VP1 protein
structure, sequence alignment with other picornaviral capsid
proteins, and/or comparative mobilities of recombinant pro-
teins of known sequence favored VP1 amino acid residues
Glu273/Ser274 as the likely 3C cleavage site (14, 31). However,
no explanation has been offered for the multiple anti-VP1
immunoreactive proteins with molecular masses (29 to 36 kDa)
intermediate between those of VP1-2A and VP1 that are ob-
served in HAV-infected cells (1, 7, 45). Some differences in the
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patterns and/or relative amounts of these products have been
detected, presumably depending on the HAV strain and the
host cell (14). Additional doubts were raised for HAV strains
that contain a Glu-to-Val substitution at the favored VP1/2A
cleavage site, resulting in a very unlikely Val/Ser substrate for
HAV 3Cpro (21, 30).
We have attempted to determine the C-terminal sequence
of HAV VP1 by using peptide sequence analysis by protease-
catalyzed [18O]H2O incorporation followed by liquid chroma-
tography ion-trap microspray tandem mass spectrometry (LC-
MS/MS) of purified HAV VP1. The technique involves the
incorporation of 18O into all a-carboxy groups liberated during
the enzyme-catalyzed partial hydrolysis of the protein, fol-
lowed by MS to identify the C-terminal peptide as the only
peptide that did not incorporate any 18O (33, 34, 36, 41, 46).
The application of this LC-MS/MS approach has led to the
successful identification and sequence analysis of the C-termi-
nal peptides from HAV VP1. Interestingly, our analyses indi-
cate the presence of a mixture of VP1 molecules in the mature
hepatitis A virions, containing consecutive amino acid residues
from VP1-274 to VP1-272 as C termini.
MATERIALS AND METHODS
HAV cDNA and cloning. HAV sequences corresponding to various lengths of
the coding region were introduced into the plasmid pTM1 (27) to allow tran-
scription control from the T7 promoter and translation under control of the
encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES). pTM1
contains the EMCV 59 noncoding region (59NCR) sequences starting from
nucleotide (nt) 260 immediately downstream of the poly(C) tract up to the
translation initiation codon.
Constructs encoding various segments of the HAV genome are depicted in
Fig. 1. Construct pEHP1-2993 contains HAV cDNA from nt 740 to nt 2993
isolated from pHAV/7 (9) by digestion with AflIII and SacI. This fragment was
inserted between the NcoI and SacI sites of the plasmid pTM1. Plasmid pEHP1-
2380 was constructed by deletion of the BamHI fragment of pEHP1-2993 from
nt 2380 (HAV) to the polylinker BamHI site. The cDNA clone pEHP1-3107
contains the complete HAV P1 region originally predicted by Cohen et al. (8) up
to nt 3107, and clone pEHP1-3216 extends to nt 3216 in the HAV coding region.
In both of these clones, PCR techniques were used to introduce a stop codon
after nt 3107 or 3216, respectively. The generated fragments were inserted
between the BamHI site at nt 2380 and the XhoI site in the polylinker of plasmid
pEHP1-2993. Construct pEHP1P2 contains almost the complete P1 and P2
regions of HAV, except for the six C-terminal amino acids of P2. These se-
quences were deleted during cloning of the HAV fragment from nt 740 (AflIII)
to nt 4982 (EcoRI) derived from pHAV/7 into the EcoRI-NcoI vector fragment
of pTM1.
For expression of the HAV 3C protease, the plasmid pTM-3C was generated
by PCR to engineer HAV 3C nucleotide sequences surrounded by an AUG
codon and a stop codon. This fragment was cloned directly into the NcoI and
XhoI sites of pTM1. Plasmids pE5H-P3 and pE5H-P3m3C have been described
previously (23). pE5H-P3 contains the entire P3 coding region of HAV, includ-
ing sequences corresponding to the eight C-terminal amino acid residues of 2C;
pE5H-P3m3C contains a HindIII linker insertion at nt 5864 in the 3C coding
region that inactivates the 3C protease activity (22).
At least six independent plasmid isolates of each construct were confirmed by
analysis of restriction enzyme digests, protein expression, and immunoblotting.
Transient expression assay. Simultaneous infection with recombinant vaccinia
virus vTF7-3 (16) and transfection with plasmid DNA were described previously
(43). Briefly, six-well plates with BS-C-1 (African green monkey kidney) cells
were washed with Dulbecco’s modified Eagle’s medium (DMEM) and 4 mg of
plasmid DNA, 8 ml of Lipofectin reagent (Gibco BRL), and approximately 10
PFU of vTF7-3 per cell was added in 500 ml of DMEM to each well. Incubation
took place for 3 h at 37°C, after which 2 ml of DMEM supplemented with 10%
fetal bovine serum (FBS) was added, and incubation continued at 37°C for 16 h.
An aliquot of one-fourth of the transfected cell material was analyzed by West-
ern blot for HAV-specific protein expression.
Western blot analysis. HAV-specific proteins were identified by Western im-
munoblotting with rabbit antiserum raised to HAV VP1 (18) and HAV VP4 (42)
as primary antibodies and alkaline phosphatase-conjugated goat anti-rabbit im-
munoglobulin G-Fc (Promega) as a secondary antibody as previously described
(42).
Cells and virus. BS-C-1 cells and cells from subclone 11-1 of the FRhK-4 cell
line (17) were grown in DMEM supplemented with 10% FBS at 37°C. HAV
HM175pE, a cell culture-adapted variant derived from an early passage of
HM175 (kindly provided by L. Binn, Walter Reed Army Institute of Research,
Washington, D.C.), which was subsequently propagated in our laboratory, was
used to infect BS-C-1 cells. HM175p35 (8) was used to infect 11-1 cells. Eighty
percent confluent cell monolayers were infected by replacement of the cell
culture medium with unpurified, frozen-thawed cells that had been infected for
10 days with the particular HM175 strain. The cells were incubated for 2 h at
34.5°C, after which DMEM supplemented with 10% FBS was added to each flask
and incubation continued at 34.5°C. The cells were split 1:3 7 days postinfection.
An aliquot was used for immunofluorescence microscopy to determine the per-
centage infected (26). Infection of 100% of the cells was usually reached 10 to 14
days postinfection.
Purification of virus and viral proteins. BS-C-1 or 11-1 cells infected with
HAV and grown in 36 T150 flasks were harvested 10 to 14 days postinfection.
The cells were trypsinized and then washed once with DMEM supplemented
with 10% FBS to inhibit the trypsin and twice with DMEM without supplements.
The cell pellets were combined and resuspended in 5 volumes of RSB (10 mM
Tris-HCl [pH 7.5], 10 mM NaCl and 1.5 mM MgCl2). Cells were lysed by
addition of 10% Nonidet P-40 to a final concentration of 1% and three cycles of
FIG. 1. Schematic representation of subgenomic HAV constructs used to examine the capsid protein cleavage mediated by HAV 3C. The constructs encode various
lengths of HAV protein sequences up to the nucleotide position indicated on the right of each HAV diagram, downstream of the EMCV IRES. All plasmids contain
a T7 RNA polymerase promoter upstream of the EMCV sequence. The predicted molecular mass (MW) of each uncleaved protein is indicated to the right. A diagram
of the HAV polyprotein is shown on top for comparison.
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freezing and thawing. The suspension was adjusted to 1% sodium dodecyl sulfate
(SDS) and treated with 200 U of DNase I (Boehringer Mannheim) in 5 mM
MgCl2 for 30 min at room temperature. Cell debris was removed by centrifuga-
tion at 16,000 3 g for 10 min at 20°C. The virus was concentrated by centrifu-
gation at 150,000 3 g for 3 h at 20°C, resuspended in NET buffer (100 mM NaCl,
20 mM Tris-HCl [pH 7.5], 1 mM EDTA) containing 1% Brij 58, and again
clarified by centrifugation (16,000 3 g, 10 min, 4°C). Three milliliters of clarified
supernatant was used to dissolve 2.25 g of CsCl. The final volume was adjusted
to 5 ml with NET buffer containing 1% Brij 58. The material was subjected to two
rounds of CsCl isopycnic ultracentrifugation at 190,000 3 g for 22 h at 4°C.
Fractions of 190 ml were collected from the top of the gradient and stored at 4°C.
Five microliters of each fraction was analyzed on an SDS–12% polyacrylamide
gel at an acrylamide/bisacrylamide ratio of 29:1 and analyzed by silver staining
with purified poliovirus as a marker. HAV-positive fractions were pooled, diluted
1:10 in phosphate-buffered saline (PBS), and concentrated by centrifugation at
150,000 3 g for 3 h at 4°C. The virus pellet was resuspended in 40 ml of PBS and
stored at 270°C.
The HAV capsid proteins were separated in an SDS–12% polyacrylamide gel,
stained with Coomassie brilliant blue R250, and washed extensively with water
and the HAV VP1 band was excised from the gel and used for amino acid
sequencing.
Enzymatic cleavage of proteins in the presence of [18O]H2O. Proteins were
proteolytically cleaved in the presence of 50% [18O]H2O (Isotec, Marrisburg,
Ohio) prior to analysis by LC-MS/MS based on the procedure first described by
Rose et al. (33) and later modified by others (34, 36, 46). In the work presented
here, the method was further modified: following SDS-polyacrylamide gel elec-
trophoresis (PAGE), protein bands were washed by a method based on that of
Hellman et al. (20). The last washing step was performed with 50 mM ammo-
nium acetate (pH 6.5), enriched in 50% [18O]H2O, and 50% acetonitrile. The gel
slice was then completely dried. One tube of trypsin (Promega, Madison, Wis.)
was reconstituted with 50 ml of 50 mM acetic acid to give a concentration of 17.4
pmol/ml. An aliquot of 5 ml was further diluted with an additional 15 ml of 50 mM
ammonium acetate (pH 6.5) prepared with 50% [18O]H2O, resulting in a final
trypsin concentration of 4.35 pmol/ml. The gel was rehydrated with 5 ml of this
trypsin solution and 5-ml aliquots of 50 mM ammonium acetate (pH 6.5), en-
riched in 50% [18O]H2O, and the buffer was continuously added until the gel was
fully reswollen. After incubation at 37°C overnight, the reaction was stopped by
addition of 1/10 volume of 10% trifluoroacetic acid (TFA). The peptides were
extracted according to the protocol of Hellman et al. (20). No 18O-enriched
buffer was utilized for the extraction of the peptides.
MS. MS was performed with a Finnigan MAT LCQ ion trap mass spectrom-
eter. The instrument was equipped with a Finnigan MAT electrospray ion source
modified for microelectrospray as previously described (10, 12, 13). The electro-
spray source was coupled to a gradient, capillary high-performance liquid chro-
matography system as described below. The LCQ ion trap mass spectrometer
was operated under manual control in the Tune Plus view with the automatic
gain control (AGC) active unless stated otherwise. The AGC targets were full
MS 2 1e1008, MSn 2 2e1007, and zoom MS 2 5e1006. The default maximal
injection time of 100 ms was increased as necessary over the ions of interest to
achieve the AGC targets. The numbers of “micro scans” collected were 3, 3, and
5 for full MS, MSn, and zoom MS, respectively. The relative collision energy for
collision-induced dissociation (CID) was optimized for each ion in real time
following a mass-to-charge (m/z) and charge-dependent relationship as a guide.
In a few cases, manual control of the ion injection time was performed to
improve the quality of weaker CID product ion spectra.
LC-MS. In the initial MS analysis, tryptic peptide ions were fractionated by m/z
ratio. LC-MS analyses with the LCQ ion trap mass spectrometer were performed
with an integrated online microspray interface (13) in which the column is
contained within the microspray needle (41). The 150-mm-inner-diameter by
350-mm-outer diameter online microspray needles were pulled by using a model
P-2000 laser-based micropipette puller (Sutter Instrument Co., Novato, Calif.) to
a terminal inner diameter of approximately 5 mm. The programmed values for
heat, filament, velocity, delay, and pull strength were 400, 0, 30, 125, and 0,
respectively. The program cycled twice before separation occurred. The final
assembly and packing of the integrated microspray needle with Vydac C18 re-
verse-phase support was performed as described previously (13). LC-MS analy-
ses were performed with the Apple Macintosh controlled gradient loop micro-
capillary HPLC system developed by Davis et al. (11) and previously described
(12). Samples were analyzed with a linear gradient from 2% to 92% buffer B (A,
0.1% TFA in water; B, 90% acetonitrile, 0.07% TFA in water [vol/vol]). The
delivery of the gradient was monitored by precolumn UV detection at 200 nm
with an ABI 759A UV/VIS spectrophotometer (Applied Biosystems, Inc., Foster
City, Calif.).
MS/MS data interpretation. MS/MS spectra are obtained after CID to induce
one dissociation event per peptide ion. Thus, a daughter ion spectrum is ob-
tained. Since dissociation of a peptide can be induced at any peptide bond, from
either the NH2 or COOH termini, the spectrum can be analyzed to determine
the peptide sequence for either terminus, thus identifying the peptide. MS/MS
spectra derived from putative C-terminal peptides were evaluated and inter-
preted manually. MS/MS spectra generated from internal peptides were inter-
preted by correlation with the OWL nonredundant composite protein sequence
database version 26.0 by using the SEQUEST database searching program (15).
Following the automatic data interpretation, the MS/MS spectra were evaluated
by hand to confirm the peptide sequence assignment.
RESULTS
Transcleavage of HAV protein precursor. To examine the
products of cleavage by HAV 3Cpro on HAV capsid protein
substrates, we performed transient transfection of BS-C-1 cells
with plasmid DNAs expressing a series of partial HAV
polyprotein substrates in the presence or absence of a second
plasmid expressing HAV 3C or an inactive mutated form of
3C. HAV 3C proteins were expressed from pE5H-P3 or pE5H-
P3m3C, which produced all P3 region proteins, including 3C
and 3CD, or from pTM-3C, which produced only 3C proteins.
Simultaneous infection with recombinant vaccinia virus vTF7-3
provided T7 RNA polymerase to transcribe the different HAV
RNAs. Viral capsid proteins were detected by Western immu-
noblot analysis with antiserum against HAV VP1 or HAV
VP4. All HAV constructs used in this assay were derived from
pHAV/7 (9) and therefore contain Val at position VP1-273.
Expression of proteins from the different HAV constructs,
depicted in Fig. 1, in the presence or absence of active HAV
3C derived from pE5H-P3, was examined by immunoblotting
with antiserum against VP1, as shown in Fig. 2A and B. For
comparison, HAV proteins derived from HAV-infected BS-
C-1 cells were analyzed on the same gels (both panels, lane 2).
All constructs produced uncleaved proteins of the expected
size in the absence of HAV 3C: P1-2380, ;60 kDa; P1-2993,
;82 kDa; P1P2, ;155 kDa (Fig. 2A, lanes 3, 5, and 7); and
P1-3107, ;87 kDa and P1-3216, ;90 kDa (Fig. 2B, lanes 3 and
5). Cotransfection with pE5H-P3 (3C) generated cleavage
products detectable with antiserum against HAV VP1 in all
protein substrates except for P1-2380. The expected VP1-spe-
cific cleavage product derived from P1-2380 would be 6 kDa,
which was not likely retained on the SDS–10% polyacrylamide
gel. Expression of all proteins was decreased when the HAV
VP1-containing precursor constructs were cotransfected with
pE5H-P3, possibly due to less efficient transfection when two
plasmid DNAs were used at the same time. An immunoreac-
tive protein of about 120 kDa was detected in all samples
cotransfected with pE5H-P3, which is most likely due to an
unspecific reaction of the antibody.
In a parallel set of experiments, 3C protein sequences were
provided by cotransfection with pTM-3C, which contains only
the 3C coding sequence rather than the P3 precursor. The
cleavage products obtained from all capsid precursor proteins
were similar to those induced by pE5H-P3 (data not shown),
confirming that 3CD or other P3 precursors manifested no
additional or unique substrate recognition or proteolytic activ-
ities, different from 3C (data not shown). This conclusion was
drawn previously by other investigators (32).
The 3C-mediated cleavage of protein P1-2993 generated a
protein which migrated at a rate similar to but slightly faster
than that of VP1 (Fig. 2A, compare lane 6 to lane 2). Proteins
from the construct containing the complete P1P2 region of
HAV showed no apparent cleavage in the absence of HAV 3C
(Fig. 2A, lane 7); as expected from previous reports that HAV
2A, present in the P1P2 construct, has no proteolytic activity
(23, 38). When expressed in the presence of HAV 3C, a VP1-
immunospecific cleavage product of about 38 kDa was pro-
duced from P1P2 (Fig. 2A, lane 8). This protein comigrates
with the PX protein in HAV-infected cells (data not shown).
The proteins analyzed from cells productively infected with
HAV showed almost complete processing of PX to VP1 in this
experiment (lane 2). Very little or no protein representing the
size of VP1 was produced from P1P2 (Fig. 2A, lane 8). Trans-
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cleavage of the protein P1-3107 by HAV 3C generated a 3C-
mediated VP1-immunospecific cleavage product larger than
HAV VP1 and smaller than HAV PX (about 33 kDa) (Fig. 2B,
lane 4). The P1-3107 protein contains the originally predicted
VP1 sequence (8), which was subsequently shown to be larger
than VP1 (14). No further cleavage of this protein was induced
by 3C. A VP1-immunospecific protein of approximately 37
kDa was derived from P1-3216 in the presence of HAV 3C
(Fig. 2B, lane 6) which migrated slightly faster than HAV PX
(data not shown). Again, HAV-VP1 was not detected. Thus,
none of the P1 substrates that extended into the P2 region were
cleaved by 3C sequences at the VP1/2A junction.
To verify that the 3C protease expressed from pE5H-P3
exhibited the correct functional activity on the capsid precursor
proteins used in this study, an immunoblot analysis with anti-
serum against HAV VP4 was also performed with P1-2380,
P1-2993, and P1P2 to visualize other products of the cleavage
reactions. The expected cleavage product VP0 and the inter-
mediate VP0VP3 were produced from all precursor capsid
proteins (Fig. 2C, lanes 4, 6, and 8). The mutated HAV 3C
derived from pE5H-P3m3C failed to cleave any HAV capsid
precursors (data not shown).
The above transcleavage assays show that HAV 3C did not
cleave a variety of HAV capsid precursor proteins of different
lengths specifically between VP1 and 2A, even while catalyzing
efficient and accurate proteolysis between VP0/VP3 and VP3/
VP1. These data support the conclusions drawn from in vitro
translation studies performed in our laboratory previously
(23), but contrast with conclusions drawn from other studies
(31, 32, 38).
Preparation of HAV VP1 for C-terminal sequence analysis.
HAV HM175pE grown in BS-C-1 cells and HM175p35 grown
in 11-1 cells were harvested 10 to 14 days postinfection and
subjected to CsCl isopycnic gradient centrifugation in order to
obtain purified virions for analysis of the C-terminal amino
acids of HAV VP1. Gradient fractions were analyzed by SDS-
PAGE followed by silver staining to identify HAV-containing
fractions. The HAV-positive fractions were combined, and vi-
rus was collected by sedimentation. Virions were dissociated in
SDS, and proteins were separated on an SDS–12% polyacryl-
amide gel followed by Coomassie blue staining for visualiza-
tion and excision of HAV VP1. Figure 3, lanes 2 and 3, shows
the capsid proteins of purified HAV virions. Purified poliovirus
(PV) was separated on the same gel (lane 1), and its VP1 was
also excised from the gel as a protein control with a known C
terminus for the sequence analysis.
FIG. 2. Immunoblot analysis of HAV polyproteins expressed from cDNA in the presence of HAV 3C in BS-C-1 cells. Transient transfection was performed in the
presence of recombinant vaccinia virus vTF7-3, which carries the gene for T7 RNA polymerase. Proteins P1-2380, P1-2993, and P1P2 were expressed from plasmids
pEHP1-2380, pEHP1-2993, and pEHP1P2, respectively, in the absence (A and C, lanes 3, 5, and 7) or presence (A and C, lanes 4, 6, and 8) of HAV 3C expressed from
pE5H-P3. VP1-specific products were detected with HAV VP1 antiserum (A), and VP4-specific products were detected with HAV VP4 antiserum (C). (B)
VP1-immunoreactive proteins P1-3107 and P1-3216 expressed from plasmids pEHP1-3107 and pEHP1-3216, respectively, in the absence (lanes 3 and 5) or presence
(lanes 4 and 6) of HAV 3C expressed from pE5H-P3. Extract from mock-transfected BS-C-1 cells as a negative control (NC) and extract from HAV-infected cells as
a positive control (HAV) were analyzed on the same gel (all panels). Immunoreactive proteins VP1 (A and B), PX (A), and VP0VP3 and VP0 (C) are indicated to
the right; molecular masses of marker proteins are indicated in kilodaltons to the left (all panels).
FIG. 3. Polyacrylamide-SDS gel analysis of HAV capsid proteins. HM175p35
was propagated in 11-1 cells and purified by CsCl isopycnic gradient centrifuga-
tion. Capsid proteins were separated by SDS-PAGE (lanes 2 and 3) in compar-
ison with PV (lane 1). The gel was stained with Coomassie blue for excision of
capsid protein VP1. PV capsid proteins are indicated to the left, and HAV capsid
proteins are indicated to the right.
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Determination of C-terminal peptides by incorporation of
[18O]H2O upon proteolytic cleavage. The approach taken for
the identification of the C-terminal peptide of HAV VP1 is
based on the incorporation of 18O into all internal a-carboxy
groups liberated during the trypsin-catalyzed partial hydrolysis
of the protein, excluding 18O incorporation into the C-terminal
peptide. Figure 4 illustrates the reaction. The mass of all in-
ternal peptides will be shifted by 2 atomic mass units (amu) by
the 18O incorporation. The experiment can be carried out by
performing two parallel digests of the proteins, one of which
contains buffer prepared with regular water, the other contain-
ing buffer prepared with [18O]H2O. Comparative mass spectral
analysis of the resulting peptides would identify the C-terminal
peptide as the only one whose mass was not shifted in the
digest performed with [18O]H2O. In order to simplify the ex-
periment and to conserve sample material, only one digestion
was carried out in the presence of 50% 18O-enriched buffer. In
this case, the mass spectral analysis was expected to reveal a
characteristic isotope pattern indicating the partial incorpora-
tion of 18O for all peptides other than the C-terminal peptide.
Analysis of PV VP1 and identification of its C-terminal
peptide. To verify the feasibility of this approach, a control
experiment was performed with the poliovirus capsid protein
VP1, since the complete sequence and the C-terminal amino
acid residues are known. Following separation of the capsid
proteins by SDS-PAGE, the excised gel band containing VP1
was subjected to in-gel trypsin digestion in the presence of 50%
18O-enriched buffer as described in Materials and Methods.
Figure 5A shows the reverse-phase chromatogram of the re-
sulting peptides. Although 50% of all internal peptides are
expected to contain 18O at their COOH terminus and 50%
contain 16O at their COOH terminus, the retention times of
both species of the same peptide remain the same during
reverse-phase chromatography.
Mass spectral analysis of individual peptide peaks from Fig.
5A are shown in Fig. 6. All internal peptides generated a
characteristic isotope pattern, as illustrated in Fig. 6A and B
for two peptide peaks resolved in Fig. 5A. The isotope distri-
bution observed for these peptides indicates the presence of
two species. One contains 16O; the other has exchanged one
16O with one 18O, resulting in a net mass increase of two mass
units for 50% of the molecules (m/z of 456.2 and 458.2 and m/z
of 1,032.5 and 1,034.5, respectively). In contrast, the isotope
distribution of the polypeptide at m/z 612.1 reveals no 18O
incorporation and is therefore identified as the putative C-
terminal peptide of the protein (Fig. 6, compare panel C with
panels A and B). All panels also show the presence of peaks
with increased masses of 1 mass unit, indicating significant
amounts of other enriched stable isotopes (13C, 15N, etc.) in
the preparations. These are represented by peaks of 457.2 and
459.3 (Fig. 6A), peaks of 1,033.4 and 1,035.4 (Fig. 6B), and the
peak of 613.1 (panel C). Other peaks (m/z 460.3 in panel A and
m/z 1,036.4 in panel B) indicate smaller amounts of peptide
increased by two mass units.
The putative C-terminal peptide was subjected to MS/MS
analysis in which the ion is subjected to CID, inducing one
fragmentation per peptide. This analysis identified the se-
quence as the expected C-terminal peptide sequence as shown
in Fig. 7. The sequence AspLeuThrThrTyr (Fig. 7) can be
derived from the MS/MS spectrum by subjecting the data to
the automatic analysis routine SEQUEST as well as by manual
interpretation (for a review, see reference 39). The parent
mass of the C-terminal peptide in Fig. 6C is 612.1. During CID
of this peptide, parts of a b-ion and y-ion series can be ob-
served. The b-ions are NH2-terminal fragments derived from
successive removal of amino acids from the COOH terminus,
e.g., b5 is the entire peptide minus water, b4 lacks Tyr, etc. Ions
designated y are COOH-terminal fragments derived from suc-
cessive removal of amino acids from the NH2 terminus, e.g., y3
lacks Asp and Leu, etc. Due to the presence of two Thr resi-
dues in the peptide, additional losses of water can be observed
for several fragment ions, resulting, for example, in b5 minus
water at 576.2 (Fig. 7).
Analysis of HAV VP1 and identification of its C-terminal
peptides. HAV VP1 isolated from HM175pE was analyzed in
the same fashion as described above for PV VP1. Following
SDS-PAGE of capsid proteins, the VP1 band was excised and
subjected to proteolytic digestion in the presence of 50% 18O-
enriched buffer as described in Materials and Methods. The
digestion mixtures were analyzed by LC-MS/MS. The chro-
matogram of HAV VP1 tryptic peptides is shown in Fig. 5B.
Analysis of the resulting peptides revealed successful 50% in-
FIG. 4. Principle of 18O incorporation into the internal a-carboxyl group
upon proteolytic cleavage of the polypeptide chain. In the presence of 50%
18O-enriched buffer, 18O incorporation is excluded from the C-terminal peptide.
FIG. 5. LC-MS/MS analysis of capsid protein VP1. A reverse-phase chro-
matogram of the resulting peptides derived from the tryptic digests of PV VP1
(A) and HAV VP1 (B) is shown. The asterisks and bar indicate the regions which
identified the C-terminal peptides in further analyses.
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corporation of [18O]H2O in all peptides generated by internal
proteolytic cleavage. During LC-MS/MS analysis of this diges-
tion mixture, three doubly charged peptide ions were identified
as putative C-terminal fragments in the high-resolution scan.
All three ions indicated no incorporation of 18O (insets, Fig. 8),
and the masses calculated from the doubly charged ions ob-
served are 1,359.2 (Fig. 8A), 1,272.2 (Fig. 8B), and 1,143.2 (Fig.
8C), respectively. The three doubly charged ions were select-
ed during the LC-MS analysis for MS/MS, and the collected
spectra are displayed in Fig. 8. Upon interpretation of the spec-
tra, the sequences were identified as APLNSNAM*LPTES,
APLNSNAM*LPTE, and APLNSNAM*LPT (Fig. 8 and 9).
The star depicts the oxidation of the methionine residue which
was observed in all three peptides. The same three peptides
without methionine oxidation eluted with an expected approx-
imately 2-min delay in retention time (41). MS/MS analysis of
these peptides revealed the same sequences as those for the
peptides containing oxidized methionine (data not shown).
The MS/MS analyses revealed the same NH2-terminal frag-
ments (b-ions) (b11, b9, and b8) in all three peptides, indicating
that the N-terminal sequence (APLNSNAMLPT) of the three
peptides is identical. Since no b-ion larger than b11 can be
observed, no further sequence assignment could be made. The
differences in the three peptide sequences can be assigned,
however, by closer examination of the COOH-terminal frag-
ment (y-ion) series. By comparison of the MS/MS spectrum in
Fig. 8A with the MS/MS spectrum in Fig. 8B, a shift of the
y-ion series by 87 amu can be observed. This indicates that the
peptide in Fig. 8B is shorter by one serine residue but other-
wise identical in sequence to the peptide in panel A. The mass
difference of 87 amu observed for the parent masses correlates
well with this finding. If Fig. 8B is compared to Fig. 8C, a shift
of the y-ion series of an additional 129 amu can be observed,
indicating that the last peptide is shorter by one glutamate
residue, again consistent with the difference between the pa-
rental masses. Since the N-terminal sequences of all three
peptides are identical, the sequence differences of the three
peptides must be located in the two last C-terminal amino
acids. This is confirmed by the fact that the offset of the y-ion
series by 87 amu and 129 amu, respectively, can be found for
the complete y-ion series. A sequence difference located in the
middle of the molecule would be accompanied by identical
masses of smaller y-ions.
The above C-terminal LC-MS/MS analysis of HAV HM175pE
identified three peptides with consecutive amino acids Thr,
Glu, and Ser as C-terminal ends of HAV VP1. Alignment with
the amino acid sequence of HAV VP1 localized these C-
terminal peptides to VP1-Ala262 through VP1-Thr272, VP1-
Ala262 through VP1-Glu273, and VP1-Ala262 through VP1-
Ser274 (Fig. 9). In contrast, the analysis of PV VP1 showed a
single peptide ending in Tyr at the C terminus of VP1 (Fig. 9).
The HAV strain HM175pE contains the amino acid Pro at
position VP1-271 and Glu at position VP1-273. Some cell
culture-adapted HAV strains derived from HM175, however,
contain VP1-271Ser and VP1-273Val at these positions. To
determine the influence of a different amino acid within the
FIG. 6. Mass spectral analysis of individual peptide peaks from the reverse-
phase chromatogram of PV VP1 (Fig. 5A). The ion signals of two representative
peptides for which 50% of the molecules have incorporated 18O are shown
([M2H]1, 456.2 [A] and 1,032.5 [B]). The isotope distribution in panels A and
B indicates the mixture of two peptide species, one containing 16O (peaks of
456.2 and 1,032.5); the other species has exchanged one 16O for one 18O resulting
in a net mass increase by two mass units for 50% of the molecules (peaks of 458.2
and 1,034.5). In contrast, the isotope distribution of the [M2H]1 ion at m/z 612.1
reveals no 18O incorporation (C) and therefore is the carboxy-terminal peptide.
FIG. 7. MS/MS analysis of the putative C-terminal peptide of PV VP1. The
MS/MS spectrum of the [M2H]1 ion at m/z 612.1 was generated during the
LC-MS/MS analysis of the PV VP1 tryptic digestion mixture. The fragmentation
pattern reveals the C-terminal peptide expected sequence. The b-ions are NH2-
terminal fragments derived from successive removal of amino acids from the
COOH terminus, and the y-ions are COOH-terminal fragments derived from
successive removal of amino acids from the NH2 terminus.
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identified C terminus of HAV VP1, we also performed C-ter-
minal sequencing by LC-MS/MS of purified virions of HAV
HM175p35, the variant with the Pro271Ser and Glu273Val
substitutions. The LC-MS/MS analysis of HM175p35 again
identified multiple amino acid residues at the C terminus of
HAV VP1 (Fig. 9). In contrast to the C termini revealed from
HM175pE, only two peptides with VP1-274Ser and VP1-
272Thr, respectively, representing the C terminus of VP1 were
identified. The amino acid valine at position VP1-273 in this
HAV variant does not seem to present a suitable target for
proteolysis or else does not generate a stable product and is
rapidly further processed. In both strains of HAV, the predom-
inant species of VP1 molecules present in mature virions con-
tained Ser274 as their C termini.
DISCUSSION
Most of the cleavages that generate the functional HAV
proteins from their polyprotein precursors have been identified
and are mediated by the viral protease 3C. The primary scis-
sion of the HAV polyprotein occurs between 2A and 2B (25),
and PX (VP1-2A) accumulates as a major protein intermedi-
ate (1). The process by which VP1 is released from PX is still
unclear. No autocatalytic activity of 2A has been observed.
Demonstration that 3Cpro could catalyze cleavage of a peptide
containing VP1-2A sequences in vitro provided support for the
general assumption that 3C, the only identified viral protease,
FIG. 9. C-terminal sequence of capsid protein VP1 determined by trypsin-
catalyzed 18O incorporation followed by LC-MS/MS. An asterisk indicates that
oxidation of the methionine residue was detected in all HAV VP1 peptides. The
predominant C-terminal amino acid (aa) of HAV VP1 detected in both cases was
Ser274.
FIG. 8. MS/MS analysis of the putative C-terminal peptides of HAV VP1 derived from HM175pE. Three ion signals corresponding to C-terminal peptides of HAV
VP1 were identified. The isotopic distribution of the doubly charged ions is shown in the insets of panels A, B, and C. The sequences were derived by MS/MS analysis.
The mass difference of 87 amu of the y-ion series generated from the peptide in panel A to the y-ion series generated from the peptide in panel B denotes the lack
of a serine residue in the peptide (marked in red). The mass difference of 129 amu similarly observed during the CID analysis of the peptides displayed in panels B
and C denotes loss of a glutamate residue in panel C (marked in green).
VOL. 73, 1999 C-TERMINAL SEQUENCE OF HEPATITIS A VIRUS PROTEIN VP1 6021
mediated the release of VP1 from PX (37, 38). Based on that
assumption, a likely cleavage site between residues Glu273 and
Ser274 of VP1 was predicted (14, 31), although never con-
firmed biochemically. The HAV 3C protease shows high spec-
ificity for a glutamine residue followed by a small amino acid
residue (30). Substitution of Gln by Glu, as was proposed for
the VP1/2A junction, is predicted to form a substrate that will
be cleaved by HAV 3C, albeit very poorly (3). Indeed, the
existence of HAV strains with a Val substitution for Glu273
raised questions about the suitability of Val/Ser as a scissile
bond for 3Cpro; subsequent studies showed it to be less effi-
ciently cleaved by 3C in vitro (31). There are no apparent
differences in virus replication rates or protein patterns be-
tween the different variants. In addition, the observation of a
series of proteins intermediate in mobility between PX and
VP1 that are present in infected cells remained unexplained by
the model that 3C-mediated cleavage of PX generated VP1.
In the present study, coexpression of several HAV capsid
precursor proteins with HAV 3C or total P3 proteins failed to
effect cleavage at the VP1/2A junction, although production of
VP0 and VP3 was readily detected. These results were consis-
tent with previous studies in our laboratory that examined
cleavages following translation in vitro of HAV constructs (23),
but appeared to contradict results from studies performed by
others (31, 38). During virus infection, cleavage of PX appears
to occur only quite late in the morphogenesis pathway of virion
particles (1, 4, 6, 47); thus, the processing of VP1-2A that
occurs in infected cells might require an assembled conforma-
tion of substrate, and the model reactions studied in vitro or in
transfected cells may not mimic the relevant biological reac-
tion.
The identification of the C-terminal amino acid(s) of pro-
teins is still one of the more challenging tasks in bioanalyses.
Chemical C-terminal sequence analysis analogous to the N-
terminal sequence analysis of protein (Edman degradation)
has been attempted for a number of years (2). However, the
approach bears several disadvantages, including the fact that
certain amino acids cannot be identified and that large
amounts of protein are required. Earlier attempts to sequence
the C terminus of HAV VP1 by using the chemical approach
failed (unpublished results); in retrospect, difficulties were
likely due to the C-terminal heterogeneity and consequent
inadequate sample loading. Another strategy to reveal the
C-terminal sequence of a polypeptide is the use of carboxy-
terminal-specific proteases in combination with mass spectral
analysis (29). Although this is a reasonably sensitive approach
for the C-terminal sequence analysis of pure peptides or
smaller proteins, it is generally unsuitable for larger biomol-
ecules and molecules in mixtures. In addition, certain amino
acids are resistant to carboxy-terminal proteolysis catalyzed by
carboxypeptidases. We also attempted mass spectral analysis of
intact HAV virion VP1; the resolution of the mass analysis was
not sufficient to determine single masses for the individual
species of the protein. Heterogeneity of the C terminus in
addition to the partial oxidation of possibly all methionine
residues contributed to the difficulty in determining the mass-
(es) of the whole protein.
Thus, we settled on a biochemical characterization of VP1
cleavage products for identification of the C terminus of HAV
VP1 from purified virions by LC-MS/MS following partial pro-
teolytic hydrolysis in the presence of 18O-enriched water. This
approach successfully identified the final carboxy-terminal
amino acid residues of VP1 molecules that are present in
mature viruses.
The protease-catalyzed [18O]H2O incorporation followed by
LC-MS/MS and identification of peptide sequences represents
a suitable alternative to the methods mentioned above.
Through the application of microspray LC-MS/MS, protein
amounts in the femtomole range become amenable to C-ter-
minal analysis. The sensitivity of this approach, which is further
demonstrated by the fact that three different C-terminal pep-
tides of VP1 could be identified in the case of HM175pE, is
superior. All terminal peptides were found in their nonoxi-
dized and oxidized forms, resulting in the presence of six C-
terminal peptides. In addition, the protein sample need not be
highly purified, as long as it resolves as a single band on an
SDS-polyacrylamide gel. In cases in which the full sequence of
the protein of interest is known, the analysis can be carried out
with mixtures as well, since only the peptides of known struc-
ture will be examined for 18O incorporation. The relevant
peptide which shows no 18O incorporation can quickly be se-
lected from the remaining peptides.
The LC-MS/MS analysis identified a mixture of three C-
terminal peptides derived from HAV HM175pE, which con-
tained three consecutive amino acids, VP1-Thr272, VP1-
Glu273, and VP1-Ser274, as C-terminal residues of HAV VP1.
The analysis of HAV HM175p35, which contains Val at posi-
tion VP1-273, identified two C-terminal peptides with VP1-
Thr272 and VP1-Ser274 as C-terminal amino acids. In both
cases, the predominant species of VP1 terminated with Ser274,
which is one residue downstream of the previously predicted
3C cleavage site. These results make it highly unlikely that
3Cpro was responsible for generating the C terminus of VP1,
since Ser274/Met275 does not have properties of a 3C cleavage
substrate and the viral protease is not known to produce het-
erogeneous ends.
We propose that 3Cpro cleaves the HAV polyprotein at the
2A/2B junction to yield P1-2A and, subsequently, at the VP3/
VP1 junction to generate VP1-2A, which participates in initial
assembly events. During virus particle formation, cellular pro-
teases may trim 2A sequences from the precursor to generate
a series of VP1-containing molecules. The precise substrate for
trimming is not known. Those that undergo sufficient trimming
(to Ser274) appear to accumulate as stable virion particles.
Trimming of the C-terminus of VP1 by cellular proteases has
been reported previously for mengovirus (5). Following 3Cpro
cleavage at a Glu/Ser junction, three amino acid residues are
removed during virus assembly, generating Leu274 as the C
terminus of the mature mengovirus VP1.
The data reported here on the heterogeneous C-terminal
amino acid residues of HAV VP1 molecules in mature virus
capsids do not provide direct information about the processing
mechanism or the enzyme(s) responsible for generating the C
terminus of VP1. The data do, however, rule out the previously
predicted Glu273/Ser274 bond as a cleavage junction that gen-
erates VP1, since the Ser274 residue is still present in the
majority of virion VP1 molecules.
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